전문 번역가, 번역 회사, 웹 페이지 및 자유롭게 사용할 수 있는 번역 저장소 등을 활용합니다.
haematological monitoring
asins ainas kontrole
마지막 업데이트: 2024-04-14
사용 빈도: 1
품질:
cytotoxicity and haematological monitoring
citotoksicitāte un hematoloģiskā kontrole
마지막 업데이트: 2024-04-14
사용 빈도: 1
품질:
therefore, haematological monitoring of patients is indicated.
tādēļ nepieciešama pacientu hematoloģiska novērošana.
마지막 업데이트: 2024-04-14
사용 빈도: 33
품질:
haematological monitoring should therefore be undertaken regularly.
tādēļ regulāri jāveic hematoloģiska uzraudzība.
마지막 업데이트: 2024-04-14
사용 빈도: 33
품질:
the dose of siklos may then be increased again under close haematological monitoring.
tad siklos devu var atkal palielināt, vienlaikus veicot rūpīgu hematoloģisko rādītāju kontroli.
마지막 업데이트: 2024-04-14
사용 빈도: 1
품질:
경고: 이 정렬은 잘못되었을 수 있습니다.
잘못된 경우 삭제해 주십시오.
haematological monitoring rosiglitazone treatment is associated with a dose-related reduction of haemoglobin levels.
asins ainas kontrole rosiglitazona terapija ir saistīta ar hemoglobīna līmeņa pazemināšanos kas atkarīga no devas.
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질:
treatment with tandemact therefore requires regular haematological monitoring (especially leucocytes and platelets).
tādēļ tandemact terapijas laikā ir regulāri jāpārbauda hematoloģiskie rādītāji (īpaši leikocītu un trombocītu skaits).
마지막 업데이트: 2024-04-14
사용 빈도: 15
품질:
periodic haematological monitoring (especially leucocytes and thrombocytes) are required during treatment with avaglim.
avaglim terapijas laikā nepieciešams regulāri kontrolēt asins ainu (it īpaši leikocītus un trombocītus).
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
careful haematological monitoring (including white blood cell and platelet count, and haemoglobin) should be performed during therapy with myocet.
myocet terapijas laikā jāveic rūpīga hematoloģisko rādītāju kontrole (ieskaitot leikocītu un trombocītu skaitu, un hemoglobīna lielumu).
마지막 업데이트: 2017-04-26
사용 빈도: 3
품질:
following routine haematological monitoring, the transdermal patch should only be applied to patients whose chemotherapy treatment is unlikely to be delayed in order to reduce the possibility of unnecessary exposure to granisetron.
pēc parastās hematoloģiskās kontroles transdermālo plāksteri drīkst uzlikt tikai tiem pacientiem, kam nav paredzama ķīmijterapijas atlikšana, lai samazinātu nevajadzīgas granisetrona iedarbības iespējamību.
마지막 업데이트: 2017-04-26
사용 빈도: 1
품질:
under exceptional circumstances a maximum dose of 35 mg/ kg b. w. / day might be justified under close haematological monitoring (see section 4.4).
izņēmuma gadījumos, pieļaujama maksimālā deva, tas ir, 35 mg/ kg ķermeņa masas, vienlaikus veicot rūpīgu hematoloģisko rādītāju kontroli (skatīt apakšpunktu 4. 4.).
마지막 업데이트: 2012-04-10
사용 빈도: 2
품질: